Search research articles
Contact Us
Filters
Showing results (331-340 of 391) with videos related to
Page
of 40
Sort By:
European Urology Focus
|
August 12, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G
Peter C Fong, Mariusz Kwiatkowski, Alessandra Mosca, et al.
The Lancet. Oncology
|
April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert Motzer, Camillo Porta, Boris Alekseev, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 20, 2011
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers
E-H Tan, C Goh, W T Lim, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Frontiers in Oncology
|
March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology
|
September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Cancer Chemotherapy and Pharmacology
|
June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
W Yeo, M Boyer, H C Chung, et al.
Page
of 40
Search research articles
Search
Showing results (331-340 of 391) with videos related to
Sort By:
Page
of 40
European Urology Focus
|
August 12, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G
Peter C Fong, Mariusz Kwiatkowski, Alessandra Mosca, et al.
The Lancet. Oncology
|
April 30, 2022
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert Motzer, Camillo Porta, Boris Alekseev, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
Investigational New Drugs
|
June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
B B Y Ma, B C Goh, W T Lim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 20, 2011
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers
E-H Tan, C Goh, W T Lim, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Frontiers in Oncology
|
March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Frontiers in Oncology
|
September 4, 2023
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Viktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Cancer Chemotherapy and Pharmacology
|
June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
W Yeo, M Boyer, H C Chung, et al.
Page
of 40